Trial Profile

Phase 2 study of TNX-1500 in Prevention of Kidney Transplant Rejection

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 12 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Feb 2025 According to Tonix Pharmaceuticals media release, the company plans to discuss phase 1 trial results with the U.S. Food and Drug Administration (FDA) in an End-of-Phase 1 meeting.Pending alignment with the FDA, a Phase 2 study of TNX-1500 in kidney transplant recipients will be pursued.
05 Mar 2024 According to Tonix Pharmaceuticals Holding Corp media release, the Phase 1 trial is intended to support dosing in a planned Phase 2 trial in kidney transplant recipients.
28 Feb 2024 According to a Tonix Pharmaceuticals Holding Corp media release, topline results expected in the third quarter of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com